EGI.L Regulatory News (EGI)

Electrical Geodesics, Inc.

Collaboration to market Hitachi's Near-infrared Spectroscopy Devices

EUGENE, OREGON, US, 29 May 2013 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, today announces the signing of a distribution agreement with Hitachi Medical Systems America, Inc. ("Hitachi").

Under the agreement, EGI will distribute Hitachi's ETG-4000 optical topography device for the non-invasive investigation of blood flow in the brain (cerebral haemodynamics) using near-infrared spectroscopy ("NIRS") in the US, Canada and Mexico. The ETG-4000 is a leading, FDA cleared, device suitable for both research and clinical use. The agreement allows EGI to sell Hitachi's NIRS device separately or in combination with EGI's Geodesic EEG Systems.

Increasingly, neurologists and neuroscientists are using multiple imaging methodologies to better understand the brain's health, function and activity. The information gleaned from NIRS on blood flow in the brain is complementary to the electrical activity data shown by EGI's dEEG products. The sensors of each of the Hitachi and EGI products interlock easily thus allowing simultaneous use to deliver enhanced functional information.

Don Tucker, PhD, Chairman and CEO, commented: "Hitachi is at the forefront in the development of NIRS technology and we are delighted to be working with them in this field and marketing the ETG-4000 alongside our own devices. Our recently launched CE marked GES 400 dEEG products were specifically designed to dovetail with a range of neurodiagnostic tools including NIRS, which is increasingly accepted as a useful imaging technology, particularly in paediatric medicine where EGI's products are also strong. We anticipate that our new GES 400 systems will have FDA clearance later this year which would allow us to provide clinicians in the US with the powerful dEEG/NIRS combination system."

Donald G. Broomfield of Hitachi said: "EGI has a reputation as a leader in advanced neurodiagnostic technologies and a significant sales presence in the US neuroscience markets through their dEEG product range and we believe that they are the partner of choice to promote the ETG-4000 and market our products in parallel with their own."

For more information contact:

About EGI

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalize on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), magneto-encephalography (MEG), and near-infrared spectroscopy (NIRS).

About Hitachi's ETG-4000 and NIRS Imaging

Optical topography makes it possible to get a glimpse of the working brain by exploiting the different absorption spectra of oxygenated and deoxygenated haemoglobin in the near-infrared region of light. The technology opens a new window to the workings of the human brain through the visualisation of blood flow. After positioning the easy-to-use probes on the head, the ETG-4000 allows the measurement of changing haemoglobin concentrations at multiple brain sites in real-time. Its comfortable sensor design makes the product ideal for use with patients or all ages, including adults, neonates, children, and the elderly. An array of probe configurations of different sizes and number of measurement channels (24-52) provides flexibility for both research and clinical applications.

In April 2013 EGI commenced trading on the London Stock Exchange AIM market under the symbol EGI.L. See www.egi.com for more information on the Company.